Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 29 | 2023 | 112 | 11.890 |
Why?
|
Adenoma | 16 | 2023 | 60 | 8.760 |
Why?
|
Colonoscopy | 30 | 2023 | 73 | 8.190 |
Why?
|
Colonic Polyps | 13 | 2023 | 34 | 5.970 |
Why?
|
Early Detection of Cancer | 14 | 2020 | 104 | 3.720 |
Why?
|
Neoplasms, Second Primary | 5 | 2022 | 40 | 2.750 |
Why?
|
Mass Screening | 6 | 2021 | 182 | 1.930 |
Why?
|
DNA Methylation | 5 | 2022 | 165 | 1.810 |
Why?
|
Barrett Esophagus | 4 | 2020 | 16 | 1.710 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2022 | 25 | 1.550 |
Why?
|
Capsule Endoscopy | 2 | 2021 | 4 | 1.420 |
Why?
|
Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.300 |
Why?
|
Humans | 53 | 2023 | 28408 | 1.260 |
Why?
|
Esophagoscopy | 5 | 2021 | 15 | 1.130 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2018 | 42 | 1.110 |
Why?
|
Population Surveillance | 3 | 2018 | 110 | 1.080 |
Why?
|
Adenomatous Polyps | 3 | 2017 | 4 | 1.080 |
Why?
|
Endoscopy, Gastrointestinal | 3 | 2021 | 11 | 1.070 |
Why?
|
Colon | 4 | 2018 | 142 | 1.070 |
Why?
|
Guideline Adherence | 2 | 2016 | 65 | 0.980 |
Why?
|
Middle Aged | 23 | 2021 | 9254 | 0.950 |
Why?
|
Esophageal Neoplasms | 3 | 2020 | 54 | 0.920 |
Why?
|
Diagnostic Errors | 2 | 2014 | 30 | 0.870 |
Why?
|
Gastroenterology | 3 | 2019 | 10 | 0.810 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2022 | 2 | 0.810 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2022 | 2 | 0.790 |
Why?
|
Intestine, Small | 1 | 2021 | 34 | 0.720 |
Why?
|
Aged | 19 | 2021 | 9262 | 0.710 |
Why?
|
Male | 22 | 2021 | 15273 | 0.700 |
Why?
|
Female | 22 | 2021 | 15708 | 0.690 |
Why?
|
Esophageal and Gastric Varices | 1 | 2020 | 3 | 0.690 |
Why?
|
Carcinoma | 2 | 2022 | 69 | 0.680 |
Why?
|
Adenocarcinoma | 3 | 2019 | 147 | 0.660 |
Why?
|
Quality of Health Care | 2 | 2022 | 126 | 0.650 |
Why?
|
No-Show Patients | 1 | 2019 | 1 | 0.640 |
Why?
|
Poverty Areas | 1 | 2019 | 9 | 0.640 |
Why?
|
Censuses | 1 | 2019 | 9 | 0.640 |
Why?
|
Esophagus | 2 | 2021 | 65 | 0.570 |
Why?
|
Pancreatic Neoplasms | 2 | 2020 | 97 | 0.570 |
Why?
|
Retrospective Studies | 10 | 2023 | 3609 | 0.560 |
Why?
|
Residence Characteristics | 1 | 2019 | 214 | 0.560 |
Why?
|
Precancerous Conditions | 2 | 2018 | 25 | 0.560 |
Why?
|
Cecum | 1 | 2016 | 12 | 0.540 |
Why?
|
Lymphoid Tissue | 1 | 2016 | 10 | 0.540 |
Why?
|
Clinical Competence | 2 | 2016 | 249 | 0.540 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 30 | 0.520 |
Why?
|
Clinical Decision-Making | 1 | 2016 | 44 | 0.510 |
Why?
|
Biopsy | 5 | 2021 | 220 | 0.500 |
Why?
|
Colorectal Surgery | 1 | 2015 | 2 | 0.490 |
Why?
|
Radiography, Thoracic | 1 | 2015 | 28 | 0.490 |
Why?
|
Colonic Neoplasms | 3 | 2022 | 61 | 0.490 |
Why?
|
Biomarkers, Tumor | 2 | 2013 | 202 | 0.470 |
Why?
|
Hyperplasia | 3 | 2021 | 20 | 0.470 |
Why?
|
Risk Factors | 5 | 2021 | 2408 | 0.450 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2013 | 11 | 0.440 |
Why?
|
Practice Patterns, Physicians' | 1 | 2015 | 122 | 0.440 |
Why?
|
Patient Compliance | 1 | 2015 | 164 | 0.440 |
Why?
|
Intestines | 1 | 2014 | 99 | 0.430 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 320 | 0.380 |
Why?
|
Intestinal Mucosa | 4 | 2022 | 192 | 0.360 |
Why?
|
Colectomy | 1 | 2010 | 23 | 0.350 |
Why?
|
Cohort Studies | 5 | 2018 | 1926 | 0.350 |
Why?
|
Colitis, Ulcerative | 1 | 2010 | 64 | 0.340 |
Why?
|
Neoplasm Staging | 6 | 2020 | 371 | 0.340 |
Why?
|
Prospective Studies | 4 | 2021 | 1805 | 0.330 |
Why?
|
Chi-Square Distribution | 3 | 2015 | 146 | 0.310 |
Why?
|
United States | 4 | 2020 | 2197 | 0.310 |
Why?
|
Logistic Models | 3 | 2015 | 395 | 0.290 |
Why?
|
Incidence | 3 | 2019 | 773 | 0.290 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 36 | 0.280 |
Why?
|
Graft vs Host Disease | 1 | 2007 | 55 | 0.270 |
Why?
|
Area Under Curve | 2 | 2019 | 62 | 0.270 |
Why?
|
Endoscopic Mucosal Resection | 2 | 2023 | 2 | 0.270 |
Why?
|
Treatment Outcome | 4 | 2023 | 3615 | 0.240 |
Why?
|
Academic Medical Centers | 2 | 2016 | 137 | 0.230 |
Why?
|
Intestinal Polyposis | 1 | 2023 | 1 | 0.220 |
Why?
|
Hyperthermia, Induced | 1 | 2023 | 6 | 0.220 |
Why?
|
Severity of Illness Index | 1 | 2007 | 986 | 0.220 |
Why?
|
Surgical Instruments | 1 | 2023 | 25 | 0.210 |
Why?
|
Risk Assessment | 3 | 2020 | 676 | 0.210 |
Why?
|
Prognosis | 4 | 2018 | 825 | 0.200 |
Why?
|
Adult | 6 | 2020 | 8097 | 0.200 |
Why?
|
Benchmarking | 1 | 2022 | 37 | 0.200 |
Why?
|
Esophageal pH Monitoring | 1 | 2021 | 2 | 0.190 |
Why?
|
MicroRNAs | 1 | 2022 | 54 | 0.190 |
Why?
|
Zenker Diverticulum | 1 | 2021 | 1 | 0.190 |
Why?
|
Endosonography | 2 | 2020 | 12 | 0.180 |
Why?
|
Gastrointestinal Transit | 1 | 2021 | 11 | 0.180 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 24 | 0.180 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2021 | 20 | 0.180 |
Why?
|
Pancreatitis, Chronic | 1 | 2020 | 1 | 0.180 |
Why?
|
Pancreatic Cyst | 1 | 2020 | 5 | 0.180 |
Why?
|
Observer Variation | 1 | 2021 | 102 | 0.180 |
Why?
|
Ikaros Transcription Factor | 1 | 2020 | 2 | 0.180 |
Why?
|
Circulating Tumor DNA | 1 | 2020 | 5 | 0.180 |
Why?
|
Transaminases | 1 | 2020 | 7 | 0.180 |
Why?
|
Gastroparesis | 1 | 2020 | 2 | 0.180 |
Why?
|
Magnets | 1 | 2020 | 3 | 0.170 |
Why?
|
Feasibility Studies | 1 | 2021 | 231 | 0.170 |
Why?
|
Epithelial Cells | 2 | 2013 | 84 | 0.170 |
Why?
|
Aged, 80 and over | 5 | 2020 | 4853 | 0.170 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.170 |
Why?
|
Bariatric Surgery | 1 | 2020 | 52 | 0.160 |
Why?
|
Databases, Factual | 1 | 2021 | 358 | 0.160 |
Why?
|
Appointments and Schedules | 1 | 2019 | 14 | 0.160 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2018 | 2 | 0.150 |
Why?
|
ROC Curve | 1 | 2019 | 144 | 0.150 |
Why?
|
Quality Improvement | 1 | 2020 | 161 | 0.150 |
Why?
|
Simulation Training | 1 | 2019 | 38 | 0.150 |
Why?
|
Forecasting | 1 | 2019 | 103 | 0.150 |
Why?
|
Proof of Concept Study | 1 | 2018 | 12 | 0.150 |
Why?
|
Reproducibility of Results | 1 | 2021 | 735 | 0.150 |
Why?
|
Genetic Testing | 1 | 2018 | 59 | 0.150 |
Why?
|
Colonoscopes | 1 | 2018 | 1 | 0.150 |
Why?
|
Brain Neoplasms | 1 | 2018 | 88 | 0.140 |
Why?
|
Referral and Consultation | 1 | 2018 | 91 | 0.140 |
Why?
|
Sex Factors | 2 | 2018 | 475 | 0.140 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 58 | 0.140 |
Why?
|
CpG Islands | 1 | 2017 | 54 | 0.140 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 27 | 0.140 |
Why?
|
Gastroenterologists | 1 | 2016 | 3 | 0.140 |
Why?
|
Age Factors | 2 | 2018 | 781 | 0.130 |
Why?
|
Portal Vein | 1 | 2017 | 47 | 0.130 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 86 | 0.130 |
Why?
|
Ultrasonography, Interventional | 1 | 2017 | 76 | 0.130 |
Why?
|
Documentation | 1 | 2016 | 29 | 0.130 |
Why?
|
Tertiary Care Centers | 1 | 2016 | 67 | 0.130 |
Why?
|
Liver Neoplasms | 1 | 2017 | 105 | 0.130 |
Why?
|
Hospitals, Community | 1 | 2015 | 14 | 0.120 |
Why?
|
Rectal Neoplasms | 1 | 2015 | 14 | 0.120 |
Why?
|
Case-Control Studies | 2 | 2013 | 593 | 0.120 |
Why?
|
Analysis of Variance | 1 | 2015 | 269 | 0.120 |
Why?
|
Microsatellite Instability | 1 | 2014 | 9 | 0.120 |
Why?
|
Metaplasia | 1 | 2014 | 7 | 0.120 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 517 | 0.120 |
Why?
|
Stomach | 1 | 2014 | 15 | 0.120 |
Why?
|
Cross-Sectional Studies | 2 | 2016 | 932 | 0.110 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 492 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 81 | 0.110 |
Why?
|
Mast Cells | 1 | 2013 | 18 | 0.110 |
Why?
|
Internship and Residency | 1 | 2016 | 219 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 42 | 0.100 |
Why?
|
Colitis | 1 | 2013 | 37 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 50 | 0.100 |
Why?
|
Macrophages | 1 | 2013 | 108 | 0.100 |
Why?
|
Time Factors | 1 | 2016 | 1490 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 730 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 128 | 0.090 |
Why?
|
Follow-Up Studies | 1 | 2013 | 1858 | 0.080 |
Why?
|
Immunohistochemistry | 2 | 2019 | 362 | 0.070 |
Why?
|
Transplantation Conditioning | 1 | 2007 | 43 | 0.070 |
Why?
|
Drug Resistance | 1 | 2007 | 47 | 0.070 |
Why?
|
Diarrhea | 1 | 2007 | 33 | 0.070 |
Why?
|
Acute Disease | 1 | 2007 | 208 | 0.070 |
Why?
|
Apoptosis | 1 | 2007 | 205 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2007 | 117 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 140 | 0.070 |
Why?
|
Transplantation, Homologous | 1 | 2007 | 281 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2010 | 1384 | 0.070 |
Why?
|
Reoperation | 1 | 2010 | 917 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2007 | 117 | 0.060 |
Why?
|
Neoplasm Invasiveness | 2 | 2018 | 89 | 0.060 |
Why?
|
Fecal Incontinence | 1 | 2005 | 3 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2005 | 211 | 0.050 |
Why?
|
Carcinogenesis | 1 | 2022 | 25 | 0.050 |
Why?
|
Manometry | 1 | 2021 | 17 | 0.050 |
Why?
|
Endoscopes | 1 | 2021 | 9 | 0.050 |
Why?
|
Pyloromyotomy | 1 | 2020 | 1 | 0.040 |
Why?
|
Pylorus | 1 | 2020 | 2 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 8 | 0.040 |
Why?
|
Gastric Emptying | 1 | 2020 | 13 | 0.040 |
Why?
|
Biopsy, Fine-Needle | 1 | 2020 | 61 | 0.040 |
Why?
|
Gastroplasty | 1 | 2020 | 28 | 0.040 |
Why?
|
Inventions | 1 | 2019 | 2 | 0.040 |
Why?
|
Epidemiological Monitoring | 1 | 2019 | 8 | 0.040 |
Why?
|
Biomedical Technology | 1 | 2019 | 8 | 0.040 |
Why?
|
Canada | 1 | 2019 | 51 | 0.040 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 32 | 0.040 |
Why?
|
Watchful Waiting | 1 | 2019 | 12 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2019 | 34 | 0.040 |
Why?
|
Gastric Bypass | 1 | 2020 | 70 | 0.040 |
Why?
|
Models, Anatomic | 1 | 2019 | 39 | 0.040 |
Why?
|
Virtual Reality | 1 | 2019 | 13 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 206 | 0.040 |
Why?
|
Microscopy, Confocal | 1 | 2019 | 93 | 0.040 |
Why?
|
Obesity, Morbid | 1 | 2020 | 104 | 0.040 |
Why?
|
Internationality | 1 | 2018 | 25 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2018 | 95 | 0.040 |
Why?
|
Societies, Medical | 1 | 2019 | 154 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2018 | 108 | 0.040 |
Why?
|
Videotape Recording | 1 | 2018 | 29 | 0.040 |
Why?
|
Imaging, Three-Dimensional | 1 | 2019 | 199 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 352 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2018 | 110 | 0.040 |
Why?
|
Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.040 |
Why?
|
Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 1 | 0.040 |
Why?
|
Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2017 | 6 | 0.030 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2017 | 5 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2017 | 16 | 0.030 |
Why?
|
Disease Progression | 1 | 2019 | 717 | 0.030 |
Why?
|
Quality of Life | 1 | 2020 | 659 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2014 | 11 | 0.030 |
Why?
|
ras Proteins | 1 | 2014 | 10 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 21 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 35 | 0.030 |
Why?
|
Age Distribution | 1 | 2014 | 89 | 0.030 |
Why?
|
Age of Onset | 1 | 2014 | 99 | 0.030 |
Why?
|
Piroxicam | 1 | 2013 | 5 | 0.030 |
Why?
|
Tryptases | 1 | 2013 | 4 | 0.030 |
Why?
|
HT29 Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
Chromones | 1 | 2013 | 7 | 0.030 |
Why?
|
Cell Degranulation | 1 | 2013 | 6 | 0.030 |
Why?
|
Morpholines | 1 | 2013 | 12 | 0.030 |
Why?
|
Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2013 | 31 | 0.030 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2013 | 27 | 0.030 |
Why?
|
Cell Movement | 1 | 2013 | 82 | 0.030 |
Why?
|
Mutation | 1 | 2014 | 353 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2013 | 178 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 249 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2013 | 316 | 0.020 |
Why?
|
Rectum | 1 | 2011 | 46 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 96 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 435 | 0.020 |
Why?
|
Signal Transduction | 1 | 2013 | 447 | 0.020 |
Why?
|
Mice | 1 | 2013 | 1461 | 0.020 |
Why?
|
Causality | 1 | 2005 | 56 | 0.020 |
Why?
|
Psychotropic Drugs | 1 | 2005 | 27 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2005 | 107 | 0.010 |
Why?
|
Animals | 1 | 2013 | 3780 | 0.010 |
Why?
|
Health Surveys | 1 | 2005 | 88 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2005 | 137 | 0.010 |
Why?
|
Comorbidity | 1 | 2005 | 500 | 0.010 |
Why?
|
Chicago | 1 | 2005 | 939 | 0.010 |
Why?
|
Stroke | 1 | 2005 | 276 | 0.010 |
Why?
|